ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

The NOSTRADAMUS Study: Microvascular Dysfunction in Sepsis

Clinical Glycocalyx Measurement
Clinical Glycocalyx Measurement

This is a non-invasive, clinical measurement image from a real GlycoCheck test of the endothelial glycocalyx.

ALPINE, Utah - April 19, 2021 - (Newswire.com)

A new study using GlycoCheck, and co-authored by GlycoCheck Chief Science Offer, Dr. Hans Vink, reports new findings of research on patients with sepsis. The study, titled "Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study" was published in Critical Care. Critical Care is a high-quality, peer-reviewed, international clinical medical journal that provides a comprehensive overview of the intensive care field.

"For the first time, we can now determine quantitative microvascular scores that correlate very well with accepted clinical parameters in individual sepsis patients for a wide range of clinical severities," said Dr. Vink, Co-Founder of GlycoCheck.

"The new GlycoCheck software system represents a significant upgrade for researchers and healthcare practitioners," said Robert Long, CEO and Co-Founder of GlycoCheck and Microvascular Health Solutions. "For several years, GlycoCheck has been used globally in groundbreaking research to understand the complex nature of the endothelial glycocalyx."

"The NOSTRADAMUS Study confirms what we've suspected for some time," Long adds, "that GlycoCheck should be in every emergency room and hospital to quickly evaluate patients to identify the severity of septic shock."

The study concludes that new important diameter-specific quantification and differentiated analysis of RBC kinetics is a key to understand microvascular dysfunction in sepsis. MVHSdynamic, which has a broad bandwidth to detect micro-vascular (dys-) function, might serve as a valuable tool to detect microvascular impairment in critically ill patients.

The full study can be reviewed at Critical Care.

About GlycoCheck:

GlycoCheck analyzes glycocalyx, endothelium, and capillary function. It analyzes capillaries that are as small as 4 microns, so small that 100 of these tiny capillaries fit inside a human hair. In just minutes, 100,000 vessels are measured, with 1,000 measurements calculated per vessel resulting in over 100 million calculations.

GlycoCheck testing has been used as part of more than 70 peer-reviewed research studies from hospitals and universities worldwide. Learn more, or schedule a demonstration of GlycoCheck, at GlycoCheck.com.

Media Contact: Gary Hennerberg - ghennerberg@microvascular.com






Press Release Service by Newswire.com

Original Source: The NOSTRADAMUS Study: Microvascular Dysfunction in Sepsis

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.38
+0.24 (0.10%)
AAPL  273.81
+1.45 (0.53%)
AMD  215.04
+0.14 (0.07%)
BAC  56.25
+0.28 (0.50%)
GOOG  315.67
-0.01 (-0.00%)
META  667.55
+2.61 (0.39%)
MSFT  488.02
+1.17 (0.24%)
NVDA  188.61
-0.60 (-0.32%)
ORCL  197.49
+2.15 (1.10%)
TSLA  485.40
-0.16 (-0.03%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.